Santos Ana, Domingues Cátia, Jarak Ivana, Veiga Francisco, Figueiras Ana
Univ Coimbra, Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, Coimbra, Portugal.
Univ Coimbra, Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, Coimbra, Portugal; Univ Coimbra, LAQV, REQUIMTE, Faculty of Pharmacy, Portugal; Univ Coimbra, Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra, Portugal.
Eur J Pharm Biopharm. 2022 Jan;170:91-111. doi: 10.1016/j.ejpb.2021.12.003. Epub 2021 Dec 10.
The most common primary malignant tumor of bone in children is osteosarcoma (OS). Nowadays, the prognosis and the introduction of chemotherapy in OS have improved survival rates of patients. Nevertheless, the results are still unsatisfactory, especially, in patients with recurrent disease or metastatic. OS chemotherapy has two main challenges related to treatment toxicity and multiple drug resistance. In this way, nanotechnology has developed nanosystems capable of releasing the drug directly at the OS cells and decreasing the drug's toxicity. Exosomes (Exo), a cell-derived nano-sized and a phospholipid vehicle, have been recognized as important drug delivery systems in several cancers. They are involved in a variety of biological processes and are an important mediator of long-distance intercellular communication. Exo can reduce inflammation and show low toxicity in healthy cells. Furthermore, the incorporation of specific proteins or peptides on the Exo surface improves their targeting capability in several clinical applications. Due to their unique structure and relevant characteristics, Exo is a promising nanocarrier for OS treatment. This review intends to describe the properties that turn Exo into an efficient, as well as safe nanovesicle for drug delivery and treatment of OS.
儿童最常见的原发性骨恶性肿瘤是骨肉瘤(OS)。如今,骨肉瘤的预后以及化疗的引入提高了患者的生存率。然而,结果仍不尽人意,尤其是在复发或转移性疾病患者中。骨肉瘤化疗面临与治疗毒性和多药耐药性相关的两个主要挑战。通过这种方式,纳米技术开发出了能够直接在骨肉瘤细胞处释放药物并降低药物毒性的纳米系统。外泌体(Exo)是一种细胞衍生的纳米级磷脂载体,在多种癌症中被认为是重要的药物递送系统。它们参与多种生物过程,是长距离细胞间通讯的重要介质。外泌体可以减轻炎症,并且在健康细胞中显示出低毒性。此外,在外泌体表面掺入特定蛋白质或肽可提高其在多种临床应用中的靶向能力。由于其独特的结构和相关特性,外泌体是一种有前途的用于骨肉瘤治疗的纳米载体。本综述旨在描述使外泌体成为用于骨肉瘤药物递送和治疗的高效且安全的纳米囊泡的特性。